.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BB05_Fludarabine.Fludarabine

Information

Fludarabine is a purine analog used as an antineoplastic agent, primarily for the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphoma. It is approved for clinical use and typically administered intravenously.

Pharmacokinetics

Pharmacokinetics reported for adult cancer patients after intravenous administration; mixed male and female population with normal renal function.

References

1. Assouline, S, et al., & Badoux, X (2016). Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. The Lancet. Haematology 3(3) e128–e138. DOI:10.1016/S2352-3026(16)00004-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26947201

2. Ben Hassine, K, et al., & Ansari, M (2021). Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. CPT: pharmacometrics & systems pharmacology 10(9) 1043–1056. DOI:10.1002/psp4.12683 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34453497

3. Jung, D, et al., & Gobburu, JVS (2024). Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia. Transplantation and cellular therapy 30(9) 923.e1–923.e9. DOI:10.1016/j.jtct.2024.07.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38972509

Revisions

• 06/2025 initial generated model